Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
29. August 2018 08:21 ET
|
Biodesix, Inc.
BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) -- A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell...
New Data Demonstrate the Biodesix VeriStrat® Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions
30. April 2018 09:20 ET
|
Biodesix, Inc.
- First Data Showing Prognostic Value of Test Among Patients by Performance Status Presented at ACMQ Annual Meeting – - Optimizing Best Supportive Care and Avoiding Overtreatment Creates an Expected...
Study Published In Managed Care Regarding Prognostic and Cancer-Care Planning Value of Biodesix’s VeriStrat® Proteomic Test
20. September 2017 11:17 ET
|
Biodesix, Inc.
BOULDER, Colo., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Findings published in the peer-reviewed journal Managed Care showed that prognostic information provided by the Biodesix® VeriStrat test can...